The association of CHEK2 with prostate cancer was already proposed in 2003, when Dong and colleagues identified 18 unique CHEK2 mutations in 15/400 (3.75%) patients with sporadic prostate cancer and in 11/298 (3.69%) patients with familial prostate cancer [200]. This evidence concerns the gene CHEK2 and prostate carcinoma.